Share
Mark Headshot

Looking Back at National Diabetes Month 2023

As the weather in the Washington D.C., area starts ebbing from shorts and T-shirts to jeans and hoodies, Autumn signals its arrival and therefore, the focus of Endocrine News turns to our annual diabetes research and practice issue each November, to coincide with Diabetes Awareness Month. As usual, thanks to the plethora of research on...
Share

Pharm Fresh: What Pharmacological Solutions Could Play a Role in Preventing Diabetes?

EN_11_2023_COVER (002) For decades, physicians have maintained that type 2 diabetes could be delayed or even prevented altogether simply by modifying certain behaviors. Priyanka Majety, MD, talks to Endocrine News about pharmacological options that could help these patients, but lifestyle modifications are still crucial. As we enter National Diabetes Month and head toward World Diabetes Day on...
Share

Special Treatment: Highlighting Cutting-Edge Diabetes Tech

Cutting-edge advancements in endocrinology continue to move diabetes treatment in the right direction faster than ever before. The treatment of diabetes is continually evolving. More than a century ago, a diabetes diagnosis was a death sentence, and although there is not yet a cure, endless updates in diabetes care help ease the burden of both...
Share

Pharma Fridays – November 10

Zepbound_Logo_PNG An Endocrine News roundup of the week’s pharmaceutical news, breakthroughs, and general information. * FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide)...
Share

FDA Approves Lilly’s Zepbound™ (tirzepatide) for Chronic Weight Management

On November 8, the U.S. Food and Drug Administration (FDA) approved Eli Lilly and Company’s (NYSE: LLY) Zepbound™ (tirzepatide) injection, the first and only obesity treatment of its kind that activates both GIP (glucose-dependent insulinotropic polypeptide) and GLP-1 (glucagon-like peptide-1) hormone receptors. Zepbound is indicated for adults with obesity (with a BMI of 30 kg/m2 or greater), or those who...